---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Place in treatment, anticipated use, and care setting. Topics: Summary: anticipated place in therapy, Proposed initial line of therapy: monotherapy in the second- and third-line setting, Company positioning for both ESR1-mutated and ESR1 wild-type tumors, Population named in the Fast Track designation, and 13 further topics. 17 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: anticipated place in therapy

Palazestrant has no approved indication. The company plans to submit a new drug application in 2027 for monotherapy in second- and third-line ER+/HER2- metastatic breast cancer and anticipates commercial launch in 2028. The FDA Fast Track designation covers ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. In OPERA-01, participants whose disease advanced after at least one endocrine therapy given with a CDK4/6 inhibitor are enrolled “regardless of ESR1 mutation status” and, in Part 2, randomized 1:1 to palazestrant 90 mg once daily or investigator's choice of standard-of-care endocrine therapy (fulvestrant, letrozole, anastrozole, or exemestane). The company states that “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”. The approved oral agents in the same setting, elacestrant, imlunestrant, and vepdegestrant, are each indicated only for ESR1-mutated disease after at least one line of endocrine therapy, and the NCCN guideline lists elacestrant, imlunestrant, or vepdegestrant for ESR1-mutated tumors, aromatase inhibitor monotherapy as a subsequent-line option, and fulvestrant with alpelisib or capivasertib for PIK3CA, AKT1, or PTEN alterations. The ESMO 2026 guideline states that at least two lines of endocrine-based therapy can be recommended before non-endocrine therapy in endocrine-sensitive disease and that a fulvestrant–CDK4/6 inhibitor switch or, to a lesser extent, fulvestrant monotherapy may be considered in the absence of targetable alterations. The ABC8 consensus recommends switching the endocrine mechanism of action when resistance emerges, reports oral SERD hazard ratios of 0.55 to 0.62 in ESR1-mutated tumors, and states that “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials”. In one cohort treated after first-line CDK4/6 inhibitor therapy, second-line treatment was cytotoxic chemotherapy in 29.7% of 839 participants, endocrine monotherapy in 12.4%, and continued CDK4/6 inhibitor in 36.0%. Palazestrant is taken orally once daily, whereas fulvestrant is given as two intramuscular injections every 28 days, with injections “mainly requiring in-office administration”. The company plans a field force of approximately 75 to 100 representatives “to cover U.S. breast oncologists” and is studying palazestrant with ribociclib in the first line in OPERA-02, with the goal of positioning it as the “endocrine therapy of choice in the first-line setting”.

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06); [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm); [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm); [Olema Oncology third quarter 2026 results announcement (2026)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-reports-third-quarter-2026-financial-and); [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/); [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf); [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf); [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf); [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml); [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext); [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/); [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/); [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.2-2"></a>

### Proposed initial line of therapy: monotherapy in the second- and third-line setting

> “We are currently evaluating palazestrant in a pivotal Phase 3 trial, called OPERA-01, as a monotherapy in the second- and third-line setting of ER+/HER2- advanced or metastatic breast cancer.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-3"></a>

### Company positioning for both ESR1-mutated and ESR1 wild-type tumors

> “Palazestrant monotherapy in 2/3L ER+/HER2- MBC offers our first opportunity for market entry in 2028”
> “Palazestrant’s approval in ESR1 mutant and wild-type tumors in the 2/3L ER+/HER2- MBC setting would be paradigm-shifting”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-4"></a>

### Population named in the Fast Track designation

> “In patients with ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-5"></a>

### Company estimates of United States incidence and market size in the second- and third-line setting

> “Annual U.S. incidence estimated at ~40K”
> “U.S. market potential of ~$3-5B”
> “Olema internal estimate of US market.”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-6"></a>

### Planned commercial launch and prescriber audience

> “Planning for commercial launch of palazestrant as a monotherapy in 2/3L ER+/HER2- MBC anticipated in 2028”
> “Anticipated targeted field force of ~75–100 reps to cover U.S. breast oncologists”

Source: [Olema Oncology corporate presentation (2026)](https://ir.olema.com/static-files/0669229e-3ae2-4bed-a1ce-308627866d06)

<a id="topic-2.2.2.2-7"></a>

### Company positioning as an endocrine backbone and first-line combination partner

> “We believe palazestrant’s oral formulation and dual mechanism of action directly address the limitations of current endocrine therapies, such as fulvestrant, aromatase inhibitors and tamoxifen, and position palazestrant as a potential endocrine therapy of choice for the treatment of ER+ breast cancers.”
> “Our goal is to successfully demonstrate improved efficacy and a favorable tolerability profile in combination with other targeted therapies to position palazestrant as the endocrine therapy of choice in the first-line setting for advanced or metastatic ER+/HER2- breast cancer.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-8"></a>

### Planned first-line use with ribociclib (OPERA-02)

> “These data further support our thesis that palazestrant possesses key characteristics to make it a potential backbone endocrine therapy of preference for ER+/HER2- breast cancer, while also supporting the ongoing pivotal Phase 3 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- MBC, called OPERA-02.”

Source: [Olema Oncology Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)

<a id="topic-2.2.2.2-9"></a>

### Company description of endocrine sequencing in metastatic disease

> “When moving a patient from one line of therapy to the next, the standard of care is to switch to an endocrine agent with a different mechanism of action depending upon last therapy, co-morbidities, and individual patient characteristics.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-10"></a>

### ESMO guideline sequence for second-line and later endocrine-based therapy

> “Selection of second-line therapy (endocrine or non-endocrine) based on disease aggressiveness, disease extent, organ function, progression-free survival on prior ET, somatic and germline mutation status and the associated toxicity profile, can be recommended [V, B].”
> “Elacestrant [I, A; ESMO-MCBS v2.0 score: 3] or imlunestrant [I, A; ESMO-MCBS v2.0 score: 3] are recommended for patients with ESR1-mutated MBC after at least one line of ET, who preferably had a prolonged response to previous CDK4/6 inhibitor therapy.”
> “Fulvestrant–CDK4/6 inhibitor switch [II, C] or fulvestrant monotherapy (to a lesser extent) [I, C; ESMO-MCBS v2.0 score: 1] may be considered in the absence of targetable alterations.”
> “At least two lines of endocrine-based therapy can be recommended before moving to non-endocrine-based therapy in endocrine-sensitive disease [V, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.2-11"></a>

### ABC8 consensus on switching endocrine mechanism and oral SERD sequencing

> “In general, when resistance emerges, switching the mechanism of action of endocrine therapy, with or without adding targeted treatment, is recommended.”
> “The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant. Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.2-12"></a>

### Endocrine-based regimens preferred after a CDK4/6 inhibitor

> “After a CDK4/6i and ET, oncologists typically treat patients with sequential ET-based regimens as long as possible because these are usually associated with less toxicity than chemotherapy.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.2-13"></a>

### Oral once-daily administration and the outpatient care setting

> “Palazestrant is a new oral ET taken once daily that may be effective against tumors with or without a mutation in ESR1.”

Source: [Pistilli et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12802986/)

<a id="topic-2.2.2.2-14"></a>

### Intramuscular fulvestrant requires in-office administration

> “Furthermore, the injections can be painful and burdensome to patients, mainly requiring in-office administration, and oral options may be preferred.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.2-15"></a>

### Company description of fulvestrant administration

> “Fulvestrant is administered every 28 days in two 5 ml intramuscular injections into the buttocks.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.2-16"></a>

### Real-world second-line treatment after first-line CDK4/6 inhibitor in the United States

> “Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively. Fulvestrant was the most commonly prescribed endocrine monotherapy (70 patients, 8.3%).”
> “Three hundred two (36.0%) of patients continued a CDK4/6i.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.2.2-17"></a>

### Real-world second- and third-line treatment after first-line CDK4/6 inhibitor in a European cohort

> “In the second-line setting ( n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).”
> “In the third-line setting ( n = 95), treatment options were more heterogeneous, including endocrine monotherapy (2%; n = 2), targeted therapies (29%; n = 27), capecitabine (36%; n = 34), other chemotherapy (26%; n = 25), and ADCs (7%; n = 7).”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
